Metralindole
Appearance
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by DMacks (talk | contribs) at 15:52, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:52, 22 June 2020 by DMacks (talk | contribs) (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB))
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H17N3O |
Molar mass | 255.321 g·mol−1 |
3D model (JSmol) | |
|
Metralindole (Inkazan) is a reversible inhibitor of monoamine oxidase A (RIMA) which was investigated in Russia as a potential antidepressant.[1] It is structurally and pharmacologically related to pirlindole.
See also
References
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |